Clinical Trial Update: Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD [Phase 3]

View source ↗

Summary

Phase 3 trial update on the Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler dose indicator study in adults with moderate to very severe COPD; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Glycopyrronium and Formoterol Fumarate (GFF) MDI (glycopyrronium bromide; formoterol fumarate dihydrate)

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: COPD | Phase 3 | Status: COMPLETED | Results posted: 2016-12-23